A Phase I/II Study of SEL24 in Patients With Acute Myeloid Leukemia

Trial Profile

A Phase I/II Study of SEL24 in Patients With Acute Myeloid Leukemia

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs SEL 24 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Selvita
  • Most Recent Events

    • 08 Oct 2017 Status changed from recruiting to suspended.
    • 17 Mar 2017 According to a Selvita company media release, first patient has been dosed in this trial.
    • 06 Jan 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top